Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Ascending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00781-3498-95 00781-3498 Arsenic Trioxide Arsenic Trioxide 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous May 19, 2022 In Use
00143-9385-01 00143-9385 Decitabine Decitabine 50.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous April 15, 2022 In Use
00378-1201-78 00378-1201 Sorafenib Sorafenib Tosylate 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET, CRAF, BRAF Oral June 1, 2022 In Use
00409-1045-01 00409-1045 PEMETREXED PEMETREXED 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 27, 2022 In Use
00409-1060-01 00409-1060 Pemetrexed Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 20, 2022 In Use
00409-1061-01 00409-1061 Pemetrexed Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 20, 2022 In Use
00409-1703-01 00409-1703 BORTEZOMIB BORTEZOMIB 2.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 16, 2022 In Use
00409-1704-01 00409-1704 BORTEZOMIB BORTEZOMIB 1.0 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 16, 2022 In Use
00409-2188-01 00409-2188 PEMETREXED PEMETREXED 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 27, 2022 In Use
00409-3532-01 00409-3532 PEMETREXED PEMETREXED 1.0 g/40mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 27, 2022 In Use
00469-1425-21 00469-1425 Gilteritinib Xospata 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral April 30, 2022 In Use
00469-1425-90 00469-1425 Gilteritinib Xospata 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral Nov. 29, 2018 In Use
00480-4514-01 00480-4514 Pemetrexed Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 31, 2022 In Use
00480-4515-01 00480-4515 Pemetrexed Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 31, 2022 In Use
00480-4516-01 00480-4516 Pemetrexed Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 1, 2022 In Use
00781-3518-76 00781-3518 Pemetrexed disodium Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 8, 2022 In Use
00781-3519-90 00781-3519 Pemetrexed disodium Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous June 8, 2022 In Use
10019-0991-01 10019-0991 Bortezomib BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
16729-0229-03 16729-0229 Pemetrexed Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
16729-0230-11 16729-0230 Pemetrexed Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
16729-0244-38 16729-0244 Pemetrexed Pemetrexed 1.0 g/40mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
23155-0774-71 23155-0774 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 In Use
23155-0774-72 23155-0774 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 In Use
23155-0775-71 23155-0775 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 In Use
23155-0775-72 23155-0775 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 In Use
23155-0776-71 23155-0776 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 In Use
23155-0776-72 23155-0776 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 In Use
23155-0777-71 23155-0777 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 In Use
23155-0777-72 23155-0777 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 In Use
23155-0778-71 23155-0778 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 In Use
23155-0778-72 23155-0778 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 In Use
23155-0779-71 23155-0779 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 In Use
25021-0244-10 25021-0244 BORTEZOMIB BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 1, 2022 In Use
43598-0370-74 43598-0370 Pemetrexed disodium Pemetrexed disodium 1.0 g/40mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
43598-0386-62 43598-0386 Pemetrexed disodium Pemetrexed disodium 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
43598-0387-11 43598-0387 Pemetrexed disodium Pemetrexed disodium 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
43598-0458-04 43598-0458 Sorafenib Sorafenib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET, CRAF, BRAF Oral June 8, 2022 In Use
43598-0458-36 43598-0458 Sorafenib Sorafenib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, RET, CRAF, BRAF Oral June 8, 2022 In Use
50742-0340-01 50742-0340 Pemetrexed disodium Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 24, 2022 In Use
50742-0341-01 50742-0341 Pemetrexed disodium Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 24, 2022 In Use
50742-0484-01 50742-0484 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 1, 2022 In Use
51817-0586-01 51817-0586 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
54288-0109-02 54288-0109 Melphalan Hydrochloride Melphalan hydrochloride Chemotherapy Alkylating Agent Nitrogen Mustard July 2, 2021 In Use
55150-0337-01 55150-0337 BORTEZOMIB BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
55150-0381-01 55150-0381 Pemetrexed Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
55150-0382-01 55150-0382 Pemetrexed Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
55150-0383-01 55150-0383 Pemetrexed Pemetrexed 1000.0 mg/40mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
59651-0530-03 59651-0530 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
59651-0530-10 59651-0530 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
59651-0531-03 59651-0531 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use

Found 10,000 results in 6 millisecondsExport these results